Table 1.
Participant demographics and baseline characteristics. All Participants as Treated
| Characteristic | Sugammadex 2 mg/kg N = 105 |
Sugammadex 4 mg/kg N = 107 |
Sugammadex 16 mg/kg N = 68 |
Neostigmine/Glycopyrrolate N = 51 |
|---|---|---|---|---|
| Gender | ||||
| Male | 59 (56.2) | 68 (63.6) | 39 (57.4) | 36 (70.6) |
| Female | 46 (43.8) | 39 (36.4) | 29 (42.6) | 15 (29.4) |
| Age (yrs): Median (Range) | 70 (35 to 87) | 70 (24 to 92) | 71 (44 to 90) | 68 (35 to 89) |
| < 65, n (%) | 28 (27) | 41 (38) | 20 (29) | 19 (37) |
| ≥65 to ≤74, n (%) | 39 (37) | 29 (27) | 25 (37) | 20 (39) |
| > 74, n (%) | 38 (36) | 37 (35) | 23 (34) | 12 (24) |
| BMI: Mean ± SD (kg/m2) | 28.1 ± 5.5 | 28.4 ± 5.3 | 28.6 ± 5.0 | 29.3 ± 5.4 |
| Median (range) | 27.1 (15.8 to 39.6) | 28.4 (16.8 to 39.8) | 28.5 (16.4 to 39.0) | 28.9 (15.7 to 39.0) |
| < 30 kg/m2, n (%) | 67 (63.8) | 65 (60.7) | 41 (60.3) | 26 (51.0) |
| ≥30 to < 40 kg/m2, n (%) | 38 (36.2) | 42 (39.3) | 27 (39.7) | 25 (49.0) |
| ASA Class: ASA Class 3, n (%) | 79 (75.2) | 79 (73.8) | 51 (75.0) | 38 (74.5) |
| ASA Class 4, n (%) | 26 (24.8) | 28 (26.2) | 17 (25.0) | 13 (25.5) |
|
Creatinine Clearance† (mL/min) | ||||
| Mean ± SD | 88.5 ± 33.9 | 94.5 ± 40.6 | 92.8 ± 49.2 | 101.5 ± 46.3 |
| Median (range) | 82.6 (27.4 to 176.0) | 91.1 (29.3 to 227.5) | 83.8 (30.1 to 368.0) | 91.3 (39.7 to 268.9) |
| ≤30, n (%) | 1 (1.0) | 1 (0.9) | 0 | 0 |
| > 30 to ≤50, n (%) | 6 (5.7) | 10 (9.3) | 4 (5.9) | 2 (3.9) |
| > 50 to ≤80, n (%) | 42 (40.0) | 33 (30.8) | 25 (36.8) | 16 (31.4) |
| > 80, n (%) | 52 (49.5) | 54 (50.5) | 34 (50.0) | 26 (51.0) |
| Missing, n (%) | 4 (3.8) | 9 (8.4) | 5 (7.4) | 7 (13.7) |
| Rocuronium, n (%) | 65 (61.9) | 66 (61.7) | 68 (100) | 32 (62.7) |
| Mean ± SD, (mg/kg) | 1.14 ± 0.62 | 1.60 ± 0.76 | 1.60 ± 0.96 | 1.01 ± 0.50 |
| Median (range), (mg/kg) | 1.01 (0.36 to 3.23) | 1.45 (0.39 to 3.92) | 1.33 (0.43 to 5.44) | 0.83 (0.33 to 2.14) |
| Vecuronium (mg/kg), n (%) | 40 (38.1) | 41 (38.3) | 0 | 19 (37.3) |
| Mean ± SD, (mg/kg) | 0.14 ± 0.08 | 0.26 ± 0.27 | n.a. | 0.14 ± 0.07 |
| Median (range), (mg/kg) | 0.12 (0.05 to 0.49) | 0.19 (0.06 to 1.73) | n.a. | 0.13 (0.05 to 0.34) |
Abbreviations: NMBA Neuromuscular blocking agent, SD Standard deviation, n.a Not applied
†Creatinine clearance based on Cockcroft-Gault formula